Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly has gotten the U.S. Food and Drug Administration (FDA) approval for cancer drug Portrazza, which comes in a form of injection for intravenous use, 800 mg/50 mL, in combination with gemcitabine and cisplatin.
US FDA has given Lupin a go to market Blisovi Fe 1/20 Tablets and Blisovi 1.5/30 Tablets market generic versions of Warner Chilcott’s Loestrin Fe 1/20 Tablets and Loestrin Fe 1.5/30 Tablets.
Pfizer Inc on Monday said it would buy Botox maker Allergan Plc in a deal worth $160 billion (£106 billion) to slash its U.S. tax bill, rekindling a fierce political debate over the financial manoeuvre.
Tiziana Life Sciences plc, the clinical stage biotechnology company focused on oncology and immunology related drugs, has appointed a banker Willy Simon as a non-executive director.
Futura Medical, a transdermal technology specialist, has received by an European regulator clarity on the regulatory pathways for its two topical pain relief products, TPR100 (diclofenac) and TIB200 (ibuprofen).
Abzena plc will buy Philadelphia-based The Chemistry Research Solution LLC (TCRS), a specialist contract chemistry and bioconjugation company, specialized in producing and analyzing antibody drug conjugates (DACs), for $15 million
Advanced Oncotherapy, the developer of proton therapy systems for cancer treatment, has appointed Professor Stephen Myers OBE, Head of Medical Applications at CERN, as Executive Chairman of its subsidiary ADAM S.A.
The Texas AIDS Drug Assistance Program (ADAP) Advisory Committee has added Daraprim to its formulary, making the medicine more accessible and affordable to AIDS patients across the state.
A privately-held biopharmaceutical company Turing Pharmaceuticals said Monday that Daraprim will be sold to the program for $1.00 per 100-count bottle.
European Commission has approved Switzerland-based Novartis’ Entresto tablets for treating adult patients with symptomatic chronic heart failure with reduced ejection fraction.
Nearly 50 percent of Medicaid patients infected with chronic hepatitis C virus (HCV) whose doctors had prescribed newer, life-saving antiviral drugs were denied coverage to the therapies because they were not considered “a medical necessity.”